Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

• Progression-free survival at 3 years [ Time Frame: Up to three years after second transplant ] [ Designated as safety issue: No ]
  
• Response rate [ Time Frame: Up to one year after second transplant ] [ Designated as safety issue: No ]
  
• Toxicity [ Time Frame: Up to one year after second transplant ] [ Designated as safety issue: Yes ]
  

Biological: filgrastim
480 mcg beginning day +5
Drug: busulfan
11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses
Drug: cyclophosphamide
60 mg/kg IV over 2 hours x 2 days
Drug: etoposide
60 mg/kg, IV
Drug: melphalan
150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
autologous-autologous tandem hematopoietic stem cell transplantation
Radiation: radiation therapy
radiation therapy

OBJECTIVES:

Primary

• Determine the 3-year progression-free survival of patients with progressive or recurrent Hodgkin's lymphoma treated with tandem autologous stem cell transplantation (2 courses of high-dose therapy with autologous stem cell rescue).
• Determine the response rate in patients treated with this regimen.
• Determine the toxic effects of this regimen in these patients.

OUTLINE: This is a pilot study. Patients are stratified according to risk (poor risk [primary progressive, recurrent, or resistant relapse] vs good risk [first recurrence]).

• Salvage therapy (for patients with relapsed disease after achieving a previous complete response): Patients receive at least 2 courses of salvage chemotherapy or radiotherapy.
• Autologous hematopoietic stem cell collection: Patients undergo autologous hematopoietic stem cell collection. Patients with an inadequate number of collected stem cells are removed from the study.
• First preparative regimen: Patients receive high-dose melphalan IV continuously over 16 hours on day -1.
• First autologous stem cell transplantation (SCT): Patients undergo autologous SCT on day 0. They also receive filgrastim (G-CSF) IV over 30 minutes once daily beginning on day 5 and continuing until blood counts recover. At least 4-8 weeks later, patients proceed to second preparative regimen.
• Second preparative regimen: Patients receive high-dose carmustine IV over 1-2 hours on days -6, -5, and -4, etoposide IV over 4 hours on day -3, and cyclophosphamide IV over 2 hours on day -2. Beginning 36-48 hours later, patients proceed to the second autologous SCT (day 0).
• Second autologous SCT: Patients undergo second autologous SCT on day 0. Patients also receive filgrastim (G-CSF) IV over 30 minutes once daily beginning on day 5 and continuing until blood counts recover.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 34 patients will be accrued for this study.